First phase of chemical process development and scale-up for drug candidate to treat disease of multiple aetiology has been completed
Ultrafine says it has successfully completed the first phase of the chemical process development and scale-up of Cambridge Biotechnology's (CBT) lead compound, CBT1008.
Selected to enter non-clinical development for the treatment of neuropathic pain earlier this year, batches of CBT1008 produced by Ultrafine will enable CBT to complete its pre-clinical studies.
The next phase of the project will involve manufacture by Ultrafine of CBT1008 to GMP for use in clinical trials.
Ultrafine was selected to provide a range of chemical development services for CBT1008 in August 2002, initially synthesising small quantities of material to support CBT's short-term requirements. Subsequently, Ultrafine conducted extensive process development work to establish a scalable route.
Tony Sedgwick, CEO of Cambridge Biotechnology said, "We are delighted with Ultrafine's contributions to the CBT1008 development programme and look forward to continuing our relationship with them into the clinical trial phase"'.
Neuropathic pain is a disease of multiple aetiology, associated with a diverse variety of conditions including diabetic neuropathy, viral infection and back pain.
It is poorly treated by existing medication and has been a major target of pharmaceutical research.
In tests so far CBT1008 has proven to be a significant improvement over existing treatments.
